Valuation: Mercury Laboratories Limited

Market Cap 840M 8.77M 7.71M 7.19M 6.6M 12.36M 12.66M 85.29M 33.36M 416M 32.93M 32.21M 1.44B P/E 2024
17.7x
P/E 2025 31.3x
Enterprise Value 879M 9.18M 8.06M 7.53M 6.91M 12.93M 13.25M 89.25M 34.9M 435M 34.45M 33.7M 1.5B EV / Sales 2024
1.29x
EV / Sales 2025 1.36x
Free-Float
13.68%
Yield 2024
0.42%
Yield 2025 0.43%
07-25 Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-11 Mercury Laboratories Limited Announces Appointment of Binaya Kumar Panigrahi as Plant Head (Jarod Unit), Effective June 11, 2026 CI
05-29 Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-29 Mercury Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026 CI
05-29 Mercury Laboratories recommends final dividend of 3.50 rupees per share RE
04-29 Mercury Laboratories Limited Announces Resignation of Sandip Patel as Plant Head-Jarod, Effective April 28, 2026 CI
02-11 Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-11 Mercury Laboratories to establish SVP plant at 300 million rupees RE
11-11 Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-07 Mercury Laboratories Limited Announces Resignation of Mukesh Shrivastava as Vice President Marketing & Sales Designated as Senior Management Personnel, Effective from November 07, 2025 CI
11-04 Mercury Laboratories Limited Announces Appointment of Seema Salvi as Head of the Department (Dept.-Injectable Production), Effective November 04, 2025 CI
25-08-14 Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2025 CI
25-08-13 Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
1 day+1.23%
1 week-5.70%
Current month+1.18%
1 month-2.09%
3 months+6.85%
6 months+1.72%
Current year-1.87%
1 week 783
Extreme 783
835
1 month 767
Extreme 767
901.9
Current year 620.55
Extreme 620.55
928.5
1 year 620.55
Extreme 620.55
976
3 years 620.55
Extreme 620.55
1,303
5 years 390
Extreme 390
1,303
10 years 212
Extreme 212
1,303
Manager TitleAgeSince
Chief Executive Officer 74 1982-02-15
Director of Finance/CFO 54 2021-10-20
Chief Operating Officer 41 2023-11-07
Director TitleAgeSince
Chairman 74 2015-02-22
Director/Board Member 71 1982-02-15
Director/Board Member 57 2017-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%-5.70%-9.40%-1.36% 9.85M
-1.30%-1.65%+56.98%+20.33% 322B
-1.27%+3.05%+28.93%-10.20% 71.8B
-1.25%+1.43%+36.48%+90.88% 9.88B
-1.96%+0.88%+2.59%-1.56% 8.64B
+2.65%+1.04%-23.09%-5.02% 4.08B
+5.26%+5.41%-38.54%+12.12% 3.61B
-3.86%-8.12%-14.18%-2.26% 3.61B
-1.35%-2.84%+36.62%+49.40% 2.7B
-0.68%+4.21%-7.83%-5.33% 2.24B
Average -0.25%+1.15%+6.86%+14.70% 42.85B
Weighted average by Cap. -1.23%+4.47%+48.08%+15.95%

Financials

2024 2025
Net sales 756M 7.89M 6.93M 6.47M 5.94M 11.12M 11.39M 76.72M 30M 374M 29.62M 28.97M 1.29B 751M 7.84M 6.89M 6.43M 5.9M 11.05M 11.32M 76.26M 29.82M 372M 29.44M 28.8M 1.28B
Net income 56.54M 590K 519K 484K 444K 832K 852K 5.74M 2.25M 27.98M 2.22M 2.17M 96.72M 31.45M 328K 289K 269K 247K 463K 474K 3.19M 1.25M 15.56M 1.23M 1.21M 53.8M
Net Debt -25.4M -265K -233K -218K -200K -374K -383K -2.58M -1.01M -12.57M -996K -974K -43.45M 38.95M 407K 357K 333K 306K 573K 587K 3.95M 1.55M 19.27M 1.53M 1.49M 66.62M
Logo Mercury Laboratories Limited
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Employees
503
Date Price Change Volume
26-07-30 796.00 +1.23% 3
26-07-29 ₹786.30 -1.84% 75
26-07-28 ₹801.00 -0.08% 9
26-07-27 ₹801.65 -3.99% 401
26-07-24 ₹835.00 +3.37% 1
  1. Stock Market
  2. Stocks
  3. MERCURYLAB6 Stock